NCT05553470View on ClinicalTrials.gov

Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

March 3, 2022

Primary Completion Date

September 13, 2024

Study Completion Date

September 13, 2024

Conditions
Non-alcoholic Steatohepatitis (NASH)
Interventions
DRUG

Miricorilant

600 mg miricorilant

Trial Locations (3)

33104

Site 02, Miami Lakes

33136

Site 01, Miami

92377

Site 03, Rialto

Sponsors
All Listed Sponsors
lead

Corcept Therapeutics

INDUSTRY